GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » ROE %

IDEXX Laboratories (IDEXX Laboratories) ROE %

: 55.94% (As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. IDEXX Laboratories's annualized net income for the quarter that ended in Dec. 2023 was $778 Mil. IDEXX Laboratories's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1,391 Mil. Therefore, IDEXX Laboratories's annualized ROE % for the quarter that ended in Dec. 2023 was 55.94%.

The historical rank and industry rank for IDEXX Laboratories's ROE % or its related term are showing as below:

IDXX' s ROE % Range Over the Past 10 Years
Min: 57.23   Med: 326.52   Max: Negative Equity
Current: 79.34

During the past 13 years, IDEXX Laboratories's highest ROE % was Negative Equity%. The lowest was 57.23%. And the median was 326.52%.

IDXX's ROE % is ranked better than
96.33% of 218 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.24 vs IDXX: 79.34

IDEXX Laboratories ROE % Historical Data

The historical data trend for IDEXX Laboratories's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 509.31 143.73 112.68 104.58 80.74

IDEXX Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.00 118.11 92.71 71.00 55.94

Competitive Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories ROE % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's ROE % distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's ROE % falls into.



IDEXX Laboratories ROE % Calculation

IDEXX Laboratories's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=845.042/( (608.737+1484.53)/ 2 )
=845.042/1046.6335
=80.74 %

IDEXX Laboratories's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=778.084/( (1297.407+1484.53)/ 2 )
=778.084/1390.9685
=55.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


IDEXX Laboratories  (NAS:IDXX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=778.084/1390.9685
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(778.084 / 3606.404)*(3606.404 / 3173.1645)*(3173.1645 / 1390.9685)
=Net Margin %*Asset Turnover*Equity Multiplier
=21.58 %*1.1365*2.2813
=ROA %*Equity Multiplier
=24.53 %*2.2813
=55.94 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=778.084/1390.9685
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (778.084 / 958.672) * (958.672 / 981.208) * (981.208 / 3606.404) * (3606.404 / 3173.1645) * (3173.1645 / 1390.9685)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8116 * 0.977 * 27.21 % * 1.1365 * 2.2813
=55.94 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


IDEXX Laboratories ROE % Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEXX Laboratories (IDEXX Laboratories) Business Description

Address
One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.
Executives
James F Polewaczyk officer: Corporate Vice President IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky director, officer: President and CEO ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith officer: Executive Vice President C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers director, officer: President & CEO IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane officer: Executive Vice President C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt director CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Bruce L. Claflin director 7035 RIDGE ROAD, HANOVER MD 21076
Samer Abdul Samad director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lawrence D Kingsley director C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062
Asha Collins director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak director C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sharon E. Underberg officer: EVP, GC & Corporate Secretary EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650
Sophie V. Vandebroek director 6 OAK MEADOW ROAD, LINCOLN MA 01770
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451

IDEXX Laboratories (IDEXX Laboratories) Headlines

From GuruFocus

Q3 2020 IDEXX Laboratories Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 IDEXX Laboratories Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2021 IDEXX Laboratories Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 IDEXX Laboratories Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 IDEXX Laboratories Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2021 IDEXX Laboratories Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 IDEXX Laboratories Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 IDEXX Laboratories Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024